MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, JANX made $10,000K in revenue. -$23,498K in net income. Net profit margin of -234.98%.

Income Overview

Revenue
$10,000K
Net Income
-$23,498K
Net Profit Margin
-234.98%
EPS
-$0.39
Unit: Thousand (K) dollars

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
2025-03-31
2024-12-31
2024-09-30
Collaboration revenue
10,000 -3,383 439
Research and development
34,629 25,055 16,591 18,614
General and administrative
10,622 9,842 7,793 17,667
Total operating expenses
45,251 34,897 24,385 36,281
Loss from operations
-35,251 -34,897 -21,002 -35,842
Interest income
10,938 11,389 7,357 7,783
Total other income
10,938 11,389 7,357 7,783
Net loss
-24,313 -23,508 -13,645 -28,059
Unrealized gain on available-for-sale securities, net
815 1,593 -2,650 9,447
Comprehensive loss
-23,498 -21,915 -16,295 -18,612
Earnings per share, basic, total
-0.39 -0.38 -0.257 -0.51
Net loss per common share, diluted
-0.39 -0.38 -0.257 -0.51
Weighted average number of shares outstanding, diluted
62,023,685 61,791,721 -292,396.667 54,628,670
Weighted-average shares of common stock outstanding, basic
62,023,685 61,791,721 -292,396.667 54,628,670
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$23,498K Unrealized gain onavailable-for-sale securities, net$815K Interest income$10,938K Net loss-$24,313K Total other income$10,938K Loss from operations-$35,251K Collaboration revenue$10,000K Total operatingexpenses$45,251K General andadministrative$10,622K Research and development$34,629K

Janux Therapeutics, Inc. (JANX)

Janux Therapeutics, Inc. (JANX)